For all third-party payors ("TPPs") in the United States and its territories, that purchased, paid for, and/or reimbursed all or any portion of the price for Actos, ActosPlus MET, ActosPlus MET XR, Duetact, and/or Oseni, for five or more independent prescriptions, between July 1, 1999 and September 17, 2010, for purposes other than resale, a class action lawsuit may affect your rights.
- A National Third-Party Payor (“TPP”) Class has been certified in a class action lawsuit against Defendant Takeda Pharmaceuticals USA, Inc. and its parent company Defendant Takeda Pharmaceutical Company Limited (jointly, “Takeda”) and Defendant Eli Lilly & Company (“Lilly”) (collectively, “Defendants”) regarding the drug Actos. The lawsuit claims that Defendants violated the Racketeer Influenced and Corrupt Organizations Act (“RICO”) by concealing Actos’ bladder cancer risk, leading TPPs to reimburse a significant number of claims that would not have been reimbursed if not for the fraud. Defendants deny they have done anything wrong. The Court has not decided who is right.
- All TPPs in the United States and its territories, that purchased, paid for, and/or reimbursed all or any portion of the price for Actos, ActosPlus MET, ActosPlus MET XR, Duetact, and/or Oseni, for five or more independent (i.e., non-refill) prescriptions, between July 1, 1999, and September 17, 2010, for purposes other than resale are included in the Class.
- Excluded from the Class are any TPPs that have released claims covered by this lawsuit.
- Class Members' options are explained on this website. To ask to be excluded, Class Members must act before April 6, 2026.
- There is no money available now, and no guarantee there will be. However, Class Members' legal rights are affected, and Class Members have a choice to make now.